Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
September 27, 2017
Kiadis Pharma Provides Update on the Marketing Authorization Application Process for ATIR101™ in Europe
AMSTERDAM-DUIVENDRECHT, The Netherlands -- Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to ...
September 27, 2017
BrainStorm Cell Therapeutics to Present at the 2017 Disruptive Growth Company Showcase NYC Presented by SeeThruEquity and RHK Capital
HACKENSACK, N.J. and PETACH TIKVAH, Israel, Sept. 27, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative ...
September 27, 2017
DelMar Pharmaceuticals to Present at AACR Special Conference on Ovarian Cancer
VANCOUVER, British Columbia and MENLO PARK, Calif., Sept. 27, 2017 /PRNewswire/ -- DelMar Pharmaceuticals (DMPI) ("DelMar" and "the Company"), a biopharmaceutical company focused on the ...
September 27, 2017
Immune Pharmaceuticals Announces Positive Results from Ongoing Phase 2 Trial of Bertilimumab in Bullous Pemphigoid
ENGLEWOOD CLIFFS, N.J. -- (BUSINESS WIRE) -- Immune Pharmaceuticals, Inc. (IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, ...
September 27, 2017
Achaogen Announces Multiple Plazomicin Presentations at IDWeek 2017
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multidrug-resistant (MDR) gram-negative infections, ...
September 27, 2017
Bellerophon Announces $23 Million Private Placement
WARREN, N.J., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company, announced today that it has entered into a definitive securities ...
September 27, 2017
AzurRx BioPharma and Mayoly-Spindler Announce Positive MS1819-SD Phase II Data in Exocrine Pancreatic Insufficiency (EPI)
BROOKLYN, N.Y., Sept. 27, 2017 (GLOBE NEWSWIRE) -- AzurRx BioPharma Inc.(AZRX) (“AzurRx” or the “Company”), today provided an update on the first six treated patients ...
September 26, 2017
TherapeuticsMD Announces Pricing of Common Stock Offering
BOCA RATON, Fla. -- (BUSINESS WIRE) -- TherapeuticsMD, Inc. (NYSE American: TXMD) today announced the pricing of an underwritten public offering of 12.4 million shares of ...
September 26, 2017
BioTime Announces Positive Secondary and Additional Positive Long-Term Data from the Renevia® Pivotal Trial
ALAMEDA, Calif. -- (BUSINESS WIRE) -- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced ...
September 26, 2017
CytoSorbents Introduces the CytoSorb Therapeutic ECMO™ Kit at the 2017 European Society of Intensive Care Medicine Congress
MONMOUTH JUNCTION, N.J., Sept. 26, 2017 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader using CytoSorb® blood purification to treat deadly inflammation in critically ...
September 26, 2017
Selexis SA and OSE Immunotherapeutics Expand Strategic Alliance to Further Advance OSE’s OSE-172 and OSE-703 Cancer Immunotherapy Programs
GENEVA & NANTES, France -- (BUSINESS WIRE) -- Selexis SA and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) announced today the signing of two commercial license ...
September 26, 2017
Catalyst Biosciences Granted FDA Orphan Drug Designation for Subcutaneous Recombinant Human Factor IX Variant for Treatment of Hemophilia B
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug ...
September 26, 2017
EMA’s Paediatric Committee Agrees to Albireo’s A4250 Pediatric Investigation Plan
BOSTON, Sept. 26, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced ...
September 25, 2017
Prometic receives FDA clearance of its IND to initiate pivotal PBI-4050 Phase 2/3 trial in patients with idiopathic pulmonary fibrosis
LAVAL, QC , Sept. 25, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) (Prometic) today announced that its oral anti-fibrotic lead drug candidate, ...
September 25, 2017
TherapeuticsMD Announces Move to Nasdaq Global Select Market
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NYSE American:TXMD), an innovative women’s healthcare company, today announced that it will voluntarily move its stock exchange listing to the ...
September 25, 2017
BioTime Board of Directors Approves Distribution of AgeX Therapeutics Shares to BioTime Shareholders
ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, announced today that its Board ...
September 25, 2017
Aradigm Announces FDA Acceptance of NDA for Linhaliq with Priority Review Status
Aradigm Corporation (ARDM) (the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with Priority Review its New Drug ...
September 25, 2017
Bioblast Announces Effectiveness of Five to One Reverse Split
TEL AVIV, Israel, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced the effectiveness of a five ...
September 25, 2017
Key Clinical Study Showing Reversal of Refractory Septic Shock in Patients Treated with CytoSorb®
MONMOUTH JUNCTION, N.J., Sept. 25, 2017 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader using CytoSorb® blood purification to treat deadly inflammation in ...
September 25, 2017
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2017 Results
CRANBURY, N.J., Sept. 25, 2017 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of ...
Page 111 of 138